Cancer/Tumor Profiling Market

Executive Summary

Cancer/Tumor Profiling Market was valued at US $10.47 billion in 2021 and is projected to grow at 11.57% CAGR over the forecast period to reach US $20.19 billion by 2027. Cancer/Tumor Profiling Market represented US $2.06 billion opportunity over 2019-2021 and estimated to create US $9.72 billion opportunity in 2027 over 2021.

Cancer/Tumor Profiling from Consainsights analyses the Cancer/Tumor Profiling Market in the Life Sciences industry over the forecast period to 2027.

Cancer/Tumor Profiling research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Cancer/Tumor Profiling segmentation includes Technology, Cancer Type, Biomarker Type, Application, Region and Geography.

Based on the Technology, the Cancer/Tumor Profiling analysis covers COVID-19 Impact, by Technology, Immunoassays, Next Generation Sequencing, Polymerase Chain Reaction, in Situ Hybridization, Microarrays, Mass Spectrometry, Other Technologies.

In Technology segment, COVID-19 Impact, by Technology segment has highest cagr growth of 10.22%.

Based on the Cancer Type, the Cancer/Tumor Profiling analysis covers Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Other Cancers.

In Cancer Type segment, Breast Cancer segment has highest cagr growth of 10.22%.

Based on the Biomarker Type, the Cancer/Tumor Profiling analysis covers Genetic Biomarkers, Protein Biomarkers, Other Biomarkers.

In Biomarker Type segment, Genetic Biomarkers segment has highest cagr growth of 10.22%.

Based on the Application, the Cancer/Tumor Profiling analysis covers COVID-19 Impact, by Application, Research Applications, Clinical Applications.

In Application segment, COVID-19 Impact, by Application segment has highest cagr growth of 10.22%.

Based on the Region, the Cancer/Tumor Profiling analysis covers COVID-19 Impact, by Region, North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.

In Region segment, COVID-19 Impact, by Region segment has highest cagr growth of 10.22%.

Based on the region, the Cancer/Tumor Profiling analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Illumina, Inc., Qiagen N.V., Neogenomics, Inc., Sysmex Corporation, Htg Molecular Diagnostics, Inc., Helomics Corporation, Caris Life Sciences, Nanostring Technologies, Inc., Ribomed Biotechnologies, Inc., Guardant Health, Inc., Foundation Medicine, F. Hoffmann-La Roche Ltd, Genscript Biotech Corporation, Tempus Labs, Histogene X, Other Companies and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Technology

Introduction

In 2021, COVID-19 Impact, by Technology segment has the highest revenue of US $3.95 billion and is expected to grow at CAGR of 10.22% by 2027 COVID-19 Impact, by Technology segment has highest cagr growth of 10.22%.

COVID-19 Impact, by Technology

COVID-19 Impact, by Technology segment was valued at US $3.17 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $7.62 billion by 2027. COVID-19 Impact, by Technology segment represented US $0.78 billion opportunity over 2019-2021 and estimated to create US $3.67 billion opportunity in 2027 over 2021.

Immunoassays

Immunoassays segment was valued at US $2.07 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $4.96 billion by 2027. Immunoassays segment represented US $0.51 billion opportunity over 2019-2021 and estimated to create US $2.39 billion opportunity in 2027 over 2021.

Next Generation Sequencing

Next Generation Sequencing segment was valued at US $1.23 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $2.94 billion by 2027. Next Generation Sequencing segment represented US $0.30 billion opportunity over 2019-2021 and estimated to create US $1.42 billion opportunity in 2027 over 2021.

Polymerase Chain Reaction

Polymerase Chain Reaction segment was valued at US $0.85 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $2.05 billion by 2027. Polymerase Chain Reaction segment represented US $0.21 billion opportunity over 2019-2021 and estimated to create US $0.99 billion opportunity in 2027 over 2021.

in Situ Hybridization

in Situ Hybridization segment was valued at US $0.57 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $1.37 billion by 2027. in Situ Hybridization segment represented US $0.14 billion opportunity over 2019-2021 and estimated to create US $0.66 billion opportunity in 2027 over 2021.

Microarrays

Microarrays segment was valued at US $0.21 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $0.50 billion by 2027. Microarrays segment represented US $0.05 billion opportunity over 2019-2021 and estimated to create US $0.24 billion opportunity in 2027 over 2021.

Mass Spectrometry

Mass Spectrometry segment was valued at US $0.24 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $0.59 billion by 2027. Mass Spectrometry segment represented US $0.06 billion opportunity over 2019-2021 and estimated to create US $0.28 billion opportunity in 2027 over 2021.

Other Technologies

Other Technologies segment was valued at US $0.07 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $0.16 billion by 2027. Other Technologies segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.08 billion opportunity in 2027 over 2021.

Cancer Type

Introduction

In 2021, Breast Cancer segment has the highest revenue of US $4.09 billion and is expected to grow at CAGR of 10.22% by 2027 Breast Cancer segment has highest cagr growth of 10.22%.

Breast Cancer

Breast Cancer segment was valued at US $3.29 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $7.90 billion by 2027. Breast Cancer segment represented US $0.81 billion opportunity over 2019-2021 and estimated to create US $3.80 billion opportunity in 2027 over 2021.

Lung Cancer

Lung Cancer segment was valued at US $1.84 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $4.43 billion by 2027. Lung Cancer segment represented US $0.45 billion opportunity over 2019-2021 and estimated to create US $2.13 billion opportunity in 2027 over 2021.

Colorectal Cancer

Colorectal Cancer segment was valued at US $1.50 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $3.59 billion by 2027. Colorectal Cancer segment represented US $0.37 billion opportunity over 2019-2021 and estimated to create US $1.73 billion opportunity in 2027 over 2021.

Prostate Cancer

Prostate Cancer segment was valued at US $0.98 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $2.34 billion by 2027. Prostate Cancer segment represented US $0.24 billion opportunity over 2019-2021 and estimated to create US $1.13 billion opportunity in 2027 over 2021.

Melanoma

Melanoma segment was valued at US $0.37 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $0.88 billion by 2027. Melanoma segment represented US $0.09 billion opportunity over 2019-2021 and estimated to create US $0.42 billion opportunity in 2027 over 2021.

Other Cancers

Other Cancers segment was valued at US $0.44 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $1.05 billion by 2027. Other Cancers segment represented US $0.11 billion opportunity over 2019-2021 and estimated to create US $0.50 billion opportunity in 2027 over 2021.

Biomarker Type

Introduction

In 2021, Genetic Biomarkers segment has the highest revenue of US $4.81 billion and is expected to grow at CAGR of 10.22% by 2027 Genetic Biomarkers segment has highest cagr growth of 10.22%.

Genetic Biomarkers

Genetic Biomarkers segment was valued at US $3.86 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $9.27 billion by 2027. Genetic Biomarkers segment represented US $0.95 billion opportunity over 2019-2021 and estimated to create US $4.47 billion opportunity in 2027 over 2021.

Protein Biomarkers

Protein Biomarkers segment was valued at US $2.21 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $5.32 billion by 2027. Protein Biomarkers segment represented US $0.54 billion opportunity over 2019-2021 and estimated to create US $2.56 billion opportunity in 2027 over 2021.

Other Biomarkers

Other Biomarkers segment was valued at US $2.33 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $5.60 billion by 2027. Other Biomarkers segment represented US $0.57 billion opportunity over 2019-2021 and estimated to create US $2.70 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, COVID-19 Impact, by Application segment has the highest revenue of US $6.17 billion and is expected to grow at CAGR of 10.22% by 2027 COVID-19 Impact, by Application segment has highest cagr growth of 10.22%.

COVID-19 Impact, by Application

COVID-19 Impact, by Application segment was valued at US $4.95 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $11.89 billion by 2027. COVID-19 Impact, by Application segment represented US $1.21 billion opportunity over 2019-2021 and estimated to create US $5.73 billion opportunity in 2027 over 2021.

Research Applications

Research Applications segment was valued at US $1.89 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $4.55 billion by 2027. Research Applications segment represented US $0.46 billion opportunity over 2019-2021 and estimated to create US $2.19 billion opportunity in 2027 over 2021.

Clinical Applications

Clinical Applications segment was valued at US $1.56 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $3.75 billion by 2027. Clinical Applications segment represented US $0.38 billion opportunity over 2019-2021 and estimated to create US $1.80 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, COVID-19 Impact, by Region segment has the highest revenue of US $4.25 billion and is expected to grow at CAGR of 10.22% by 2027 COVID-19 Impact, by Region segment has highest cagr growth of 10.22%.

COVID-19 Impact, by Region

COVID-19 Impact, by Region segment was valued at US $3.42 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $8.20 billion by 2027. COVID-19 Impact, by Region segment represented US $0.84 billion opportunity over 2019-2021 and estimated to create US $3.95 billion opportunity in 2027 over 2021.

North America

North America segment was valued at US $2.35 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $5.65 billion by 2027. North America segment represented US $0.58 billion opportunity over 2019-2021 and estimated to create US $2.72 billion opportunity in 2027 over 2021.

Europe

Europe segment was valued at US $1.24 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $2.98 billion by 2027. Europe segment represented US $0.30 billion opportunity over 2019-2021 and estimated to create US $1.44 billion opportunity in 2027 over 2021.

Asia-Pacific

Asia-Pacific segment was valued at US $0.56 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $1.34 billion by 2027. Asia-Pacific segment represented US $0.14 billion opportunity over 2019-2021 and estimated to create US $0.65 billion opportunity in 2027 over 2021.

Latin America

Latin America segment was valued at US $0.39 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $0.95 billion by 2027. Latin America segment represented US $0.10 billion opportunity over 2019-2021 and estimated to create US $0.46 billion opportunity in 2027 over 2021.

Middle East & Africa

Middle East & Africa segment was valued at US $0.44 billion in 2019 and is projected to grow at 10.22% CAGR over the forecast period to reach US $1.06 billion by 2027. Middle East & Africa segment represented US $0.11 billion opportunity over 2019-2021 and estimated to create US $0.51 billion opportunity in 2027 over 2021.